Open Access Research Article
White Black Legal – International Law Journal · ISSN 2581-8503
Evaluating TRIPS Flexibilities and Public Welfare Strategies in India and Developing Jurisdictions
Read the Full Research Paper
Access the complete open-access article in PDF format. No login is required.
Abstract
EVALUATING
TRIPS FLEXIBILITIES AND PUBLIC WELFARE STRATEGIES IN INDIA AND DEVELOPING
JURISDICTIONS.
AUTHORED BY - DR. SYED
MOHSIN RAZA
Associate Professor
Faculty of Law, Shia P.G.
College,
University
of Lucknow, Lucknow
Abstract
The
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes binding minimum
standards for intellectual property protection all over the World Trade
Organization (WTO) member states. While intended to harmonize patent protection
and stimulate innovations, its uniform framework has generated significant
developmental concerns, particularly in countries with limited technological
capacity. In this research paper we examines TRIPS flexibilities as instruments
of regulatory balance and also evaluates their effectiveness in advancing
public welfare within India and selected Global South jurisdictions. Through a
comparative doctrinal analysis of the topic, this study argued that TRIPS
embodies a negotiated equilibration between private patent rights and sovereign
authority for protecting public interest. Articles
7 and 8 of the TRIPS Agreement emphasize technological
dissemination, social inequality and public welfare, and the prevention of
abuse of rights.
Further
the Doha Declaration on Public Health reaffirms the primacy of access to
medicines. India represents a valued paragon of strategic utilization of TRIPS
flexibilities, specially through its patent law framework and landmark
compulsory licensing practices. On the contrary many developing countries in
Africa region and Latin America have faced institutional, political, and
economic curtailments in implementing to similar safeguards. This study also
compares India’s legislative alacrity with experiences from countries such as
Brazil and South Africa to highlight variations in enforcement, political will,
and external trade pressures. The analysis reveals that while TRIPS
flexibilities formally exist, their practical effectiveness depends on domestic
legal capacity, resistance to TRIPS-Plus obligations, and regional cooperation
among developing nations. Global health emergencies have further exposed
structural inequities in access to pharmaceuticals and essential technologies, underscoring
the continuing relevance of a development-oriented interpretation of TRIPS.
This
paper reckon that TRIPS flexibilities are not exceptional divergence from
patent protection but essentially structural correctives embedded within the International
Intellectual Property Law. Strengthening their operationalization is conclusive
for reducing Global inequality within nations in alignment with Sustainable
Development Goal.
Keywords:
TRIPS Flexibilities; Public welfare; Compulsory Licensing; Global Inequality; Intellectual
Property
1.Introduction
The
global interconnectedness of intellectual property prototype through the TRIPS
Agreement marked a transformative moment in international economic governance.
By assimilating intellectual property protection into the collaborative trade
system, TRIPS exalted patent rights to enforceable international global
obligations. Nevertheless, this harmonization transpired amidst stark
evolutionary asymmetries between industrialized and developing economies. we
will examines in this paper TRIPS flexibilities as instruments of regulatory
balance and also evaluates their
effectiveness in advancing public welfare within India and selected Global
South jurisdictions. Through a comparative doctrinal analysis of the topic,
this study argued that TRIPS embodies a negotiated equilibration between
private patent rights and sovereign authority for protecting public interest.
For
cutting-edge nations, stronger patent framework incentivize research and
innovation. For evolving countries, specifically those in the Global South,
rigid protection may augment dependence on imported technologies and restrict
access to essential medicines. This conflict heightens a fundamental question:
may TRIPS accommodated developmental equity within its legal structure? In this
research paper we will explores these types of questions through a comparative
analysis of India and mentioned Global South jurisdictions. The analysis
reveals that while TRIPS flexibilities formally exist, their practical
effectiveness depends on domestic legal capacity, resistance to TRIPS-Plus
obligations, and regional cooperation among developing nations. Global health
emergencies have further exposed structural inequities in access to
pharmaceuticals and essential technologies, underscoring the continuing
relevance of a development-oriented interpretation of TRIPS.
2. Legal and conceptual Framework of the TRIPS
TRIPS
does not only works as a purely protectionist instrument but also states that,
as per Article 7 of the TRIPS elaborate that intellectual property protection
should contribute to technological innovation and global public welfare. Also
Article 8 permitted to member states of the TRIPS to adopt suitable measures
important for protecting public health and prevent abuse of intellectual
property rights.
The
TRIPS Agreement adopted in 1994 as part of the WTO framework, established
minimum international standards for the protection and enforcement of
intellectual property rights, including pharmaceutical patents.[1] Before TRIPS, many
developing countries did not grant patent protection for medicines at all;
after its adoption, all WTO members were required to provide 20-year patent
protection for pharmaceutical products and processes. [2]
This fundamentally reshaped the legal landscape for access to medicines,
effectively limiting the production and import of affordable generic drugs in
many countries.[3]
Recognizing
that rigid IP rules could harm public health, especially in resource-poor
settings, TRIPS included several legal safeguards-commonly referred to as
“flexibilities. “4 The TRIPS Agreement comprises multiple
public-health-oriented flexibilities which permits governments to balance
patent protection with access to medicines. At the foundation is sovereign
policy space, enabling countries to define strict patentability criteria,
implement pre- and post-grant opposition systems, enforce robust disclosure
requirements, and shape clear infringement standards to prevent unwarranted
monopolies. 5 When patents nonetheless create access barriers,
corrective measures are available, including compulsory licensing, government
use authorizations, competition-law interventions against abusive practices, [4] and judicial discretion to refuse provisional
injunctions where the public health is on the line. The TRIPS flexibilities
also include other pro-competitive mechanisms such as the ‘Bolar exception’,
parallel importation, and a flexible interpretation of test-data protection
under Article 39.3 each designed to facilitate timely generic entry and/or
lower prices. [5]Finally, the agreement
includes defensive safeguards: a pharmaceutical patent exemption for Least
Developed Countries extended until at least 2033.[6]
Additionally, the TRIPS Agreement does not necessitate WTO members to accept
broader protections than that stipulated in the Agreement. Together, these flexibilities
form an integrated framework that countries can use to promote access to
affordable medicines while remaining fully compliant with TRIPS. [7][8]
The
Doha Declaration on TRIPS and Public Health (2001) reaffirmed that TRIPS should
not prevent States from taking measures to protect health. 10 It
clarified that TRIPS “should be interpreted and implemented in a manner
supportive of WTO Members’ right to protect public health and, in particular,
to promote access to medicines for all. “11The Declaration precisely
confirmed the right of WTO members for granting compulsory licenses, and also
determines what a national emergency, and select their own methods for
implementing TRIPS obligations. Its also gives a basis for expanding transition
periods for LDCs and introduced mechanisms to help countries without
manufacturing capacity import generic medicines under a compulsory license.
Despite
these legal and policy possibilities, the use of TRIPS flexibilities has been
politically sensitive and procedurally complex. [9]
Legally, the Doha Declaration elucidated ambiguities in TRIPS and strengthened
the legitimacy of using flexibilities, thus implementation has depended on
national capacity and political will spheres where external pressures and
institutional constraints remains considerable. The foundation for treating
access to medicines as a human rights issue lies in the right to health,
enshrined in Article 12 of the International Covenant on Economic, Social and
Cultural Rights (ICESCR). [10] The Covenant, which came
into force in 1976 and has been ratified by over 170 countries, recognizes “the
right of everyone to the enjoyment of the highest attainable standard of
physical and mental health.” This contains
not just access to health services but also to the access to essential
medicines specifically those needed to treat life-threatening or chronic
conditions of human health.
The
United Nations (UN) Committee on Economic, Social and Cultural Rights, which
observed the implementation of the ICESCR, has interpreted this right
expansively. In its General Comment No. 14 (2000), the Committee made clear
that States have a “core obligation” to provide essential drugs, as defined by
the World Health Organization (WHO), and that this obligation is
non-derogable-meaning it cannot be delayed due to lack of resources or
capacity. [11]The General Comment also
emphasized four dimensions of access: availability, accessibility,
acceptability, and quality-standards that are widely referenced in health
policy and international law. [12]
Built-in
on this legal base, the UNHRC plays a key role in interpreting and reinforcing
the right to health throughout resolutions, special procedures, and expert
reports. Although its resolutions are not legally binding, they carry
significant normative weight. They reflect collective expectations about how
international law should be applied and serve as soft law instruments that
shape global discourse and guide State behaviour. [13][14]
During
the past 2 decades, the UNHRC has adopted multiple resolutions, examined below,
linking access to medicines with the right to health, explicitly referencing
States’ obligations under the ICESCR and encouraging the use of TRIPS
flexibilities. 17 These resolutions often underscore the
responsibility of both governments and international institutions to avoid IP
policies that undermine access, especially in low-income settings. They have
also supported the mandate of the Special Rapporteur on the Right to Health,
whose thematic reports[15] have provided detailed
legal guidance on reconciling IP rights with human rights.
These
provisions shows the embedded principle of balance. The agreement therefore
includes normative capacity for states to align patent protection with
developmental objectives.
Intellectual
property rights are conventionally specifies as incentives for innovation and
technological progress. However, contemporary scholarship increasingly examines
intellectual property through the lens of distributive justice, particularly in
the context of developing countries. Strong patent protection may stimulate
research and development, but it can also created hurdles to access where
essential technologies or medicines become unaffordable. In such circumstances,
the international intellectual property framework must balance private
proprietary interests with broader social objectives. The TRIPS Agreement
reveals this harmony through Articles 7 and 8, which emphasize that
intellectual property protection should contribute to social and economic
welfare. From this point of view, TRIPS flexibilities operate as mechanisms
that enable states to protect public health while maintaining compliance with
international trade obligations.
In
practical situation, these resolutions establish political and moral pressure
on States and international bodies. Whereas they do not obliged adherence in
the way treaty obligations do, they contribute to norm-building, influence
domestic and international health policy agendas, and are often cited by
advocacy groups, courts, and legislators as authoritative interpretations of
international law.
Eventually,
the UNHRC’s contributions aids reframe access to medicines not as an optional
policy choice but as an obligation embedded in the ICESCR. Notwithstanding
their effectiveness depends on whether States adopt the measures they
encourage-including the use of TRIPS flexibilities.
A
commitment to equity lies at the heart of the right to health. This requires
States to ensure that access to essential medicines is not determined by
socio-economic status, geographic location, or other structural factors that
systematically disadvantage certain populations.
General
Comment No. 14 makes this clear: the right to health encompasses not only
availability and affordability, but also non-discrimination and the
prioritization of vulnerable and marginalized groups. Seen through this lens,
TRIPS flexibilities are not peripheral legal tools but central mechanisms for
fulfilling core human rights obligations. By enabling competition, they allow
States to narrow price gaps that disproportionately burden low-income
households and to extend treatment to populations historically excluded from
timely or affordable care. Thus, the use of TRIPS flexibilities is not a
discretionary policy option-it is an essential means of advancing the equitable
realization of the right to health.
3. TRIPS Flexibilities
The
terminology used to refer to the policy space available for the implementation
of the TRIPS Agreement has evolved. Expressions such as “room to maneuverer,”
“margins of freedom,” “safeguards,” and “margin of discretion” were used in the
early studies and reports that identified various aspects of such space.
Currently, the diversity of legislative options available
under
said Agreement is generally known as ‘TRIPS flexibilities.”
The
term “flexibility appears in the Preamble (sixth paragraph) and in Article 66.1
of the TRIPS Agreement but it is used there with a broader meaning. It
indicates that least-developed countries (LDCs) are not bound to comply with
the TRIPS Agreement obligations (except Articles 3 through 5) during the
transition period:
In
view of the special needs and requirements of least-developed country Members,
their economic, financial and administrative constraints, and their need for
flexibility to create a viable technological base, such Members shall not be
required to apply the provisions of this Agreement, other than Articles 3, 4
and 5, for a period of...
The
terminology “TRIPS flexibilities does include the exemption for LDCs, but it
also encompasses possible variations in the manner in which the TRIPS
Agreement’s provisions are interpreted and implemented as they are applied to
countries actually subject to them. Such terminology was used for the first
time with this latter meaning in the context of the WTO in paragraph 4 of the
Doha Declaration.” Said paragraph states:
4.
We agree that the TRIPS Agreement does not and should not prevent Members from
taking measures to protect public health. Accordingly, while reiterating our
commitment to the TRIPS Agreement, we affirm that the Agreement can and should
be interpreted and implemented in a manner supportive of WTO Members’ right to
protect public health and, in particular, to promote access to medicines for
all. In this connection, we reaffirm the right of WTO Members to use, to the
full, the provisions in the TRIPS Agreement, which provide flexibility for this
purpose.”
The
Declaration confirmed the availability of a number of flexibilities. Its
adoption was a response to the concerns of developing countries about the
obstacles they faced when seeking to implement measures to promote access to
affordable medicines, without limitation to certain diseases, in the interest
of public health.20
TRIPS
incorporates several legal mechanisms designed to maintain equilibrium between
intellectual property protection and public welfare considerations. These
mechanisms, commonly referred to as “TRIPS flexibilities,” allow member states
to adapt patent protection to domestic policy needs. Among the most significant
of these safeguards are compulsory licensing, parallel importation, and
transitional arrangements and so on for least developed countries.
3.1
Compulsory Licensing
Article
31[16] permits governments to
authorize the use of patented inventions without consent under specific
conditions. This mechanism serves as a safeguard against excessive pricing and
supply shortages. Compulsory licensing has emerged as one of the most
significant safeguards within the TRIPS framework, enabling governments to
authorize the production of patented medicines without the consent of the
patent holder under specific circumstances such as public health emergencies or
unaffordable drug prices.[17]
India
operationalized this provision in its patent law framework, demonstrating the
practical relevance of TRIPS flexibilities.[18]
Compulsory
licenses for the supply of medicines to countries with a lack of or
Insufficient manufacturing capacity Compulsory licenses exclusively for the
export of Medicines can be granted under the amendment introduced to the TRIPS
Agreement in 2017 and the waiver adopted by WTO in 2003.
3.2
Parallel Importation
The
doctrine of exhaustion allows countries to import patented goods sold elsewhere
at lower prices. This enhances market competition and affordability.
3.3
Transitional Arrangements
Least
developed countries received extended timelines to implement pharmaceutical
patents, recognizing structural economic disparities.
3.4
Exemptions) for LDCs
LDCs
need not grant patents for pharmaceuticals and test data Protection at least
until 2033 under the extended transition period provided for under Article 66.1
of the TRIPS Agreement.
3.5
Government use
In
many cases governments may decide, consistently with the TRIPS Agreement, to
use patented inventions for non-commercial purposes, such as for Ensuring the
supply of essential medicines.
3.6
Test data protection – The TRIPS Agreement (Article 39.3) requires WTO members
to protect test data against unfair competition, which does not create
exclusive rights. The Agreement is complied with if legislation on unfair
competition is implemented to protect Such data.
3.7
Pre and post patent grant opposition
Procedures
before patent offices provide for the possibility for third parties to
contribute to the examination process through ‘observations’ Or ‘oppositions,’
whether before or after the grant of a patent, or both.
3.8
Use of competition law to address the misuse of IPRs – Competition law may be
Applied to correct market distortions created through the abuse of IPRs.
3.9
Bolar exception
‘Bolar
exceptions’ are important to accelerate the entry of generic Products and
promote a dynamic market for medicines.
3.10
Research or experimentation exception
This
exception allows research to be Conducted by third parties on patented
inventions, for instance, to improve on them or derive New inventions.
3.11
Disclosure requirement, particularly for biologics the full and precise
disclosure Of an invention is crucial for the patent system to perform its
informational function.
4.
India and TRIPS Flexibilities
India’s
Patent Act incorporates public interest safeguards such as strict patentability
criteria and compulsory licensing provisions. The 2012 compulsory license
granted for a life-saving cancer drug marked a significant assertion of public
health priorities within the TRIPS framework.[19]
India
has also maintained resistance against expansive TRIPS-Plus commitments in
bilateral trade negotiations, preserving domestic regulatory autonomy.
5.
Comparative Analysis
India’s
patent law framework illustrated how TRIPS flexibilities can be incorporated
into domestic legislation without violating international obligations. The
Patents Act includes provisions that allow compulsory licensing when patented
inventions are not available at reasonably affordable prices or when public
health needs are not adequately satisfied.[20]
The
landmark Natco v. Bayer compulsory licensing decision marked the first time the
Indian Patent Office authorized a generic manufacturer to produce a patented
cancer drug at a significantly reduced price.[21]
The case demonstrated that TRIPS flexibilities can operate as effective policy
tools when supported by clear legislative provisions and administrative
willingness.
Brazil
provides another example of strategic engagement with TRIPS safeguards. Rather
than frequently issuing compulsory licenses, Brazil has used the possibility of
such action as a bargaining instrument to negotiate price reductions with
pharmaceutical companies supplying antiretroviral medicines for HIV treatment
programs.[22]
In
the contrary South Africa’s experience illustrates the political resistance
that developing countries sometimes encounter when attempting to implement
public health measures affecting patent rights. Efforts to reform medicines
legislation in the late 1990s were challenged by multinational pharmaceutical
companies, leading to extensive litigation and international pressure.[23] Despite of the case was
eventually withdrawn, it demonstrates the broader geopolitical dynamics
surrounding intellectual property governance.
Bilateral
trade agreements evolvingly impose standards exceeding TRIPS obligations. These
provisions may threshold compulsory licensing grounds, extend patent terms, or
introduce data exclusivity requirements. Such developments risk undermining the
balance envisioned within TRIPS.
6. TRIPS,
Recent Global Health, and Inequality
Recent
global health conflicts revealed structural inequalities in vaccine production
and distribution. The debate surrounding momentary IP waivers highlighted
stress between innovation incentives and equitable access. The relationship
between intellectual property protection and public health has been widely
debated in international policy discussions, particularly regarding the
affordability of essential medicines in developing countries. International
organizations have emphasized that patent protection should not undermine
public health objectives.[24]
A
development-oriented interpretation of TRIPS is important to protect and
obstruct intellectual property from reinforcing global disparities.
7. Conclusion
TRIPS
flexibilities incorporates integral harmony mechanisms within international
intellectual property law. On the other hand, India’s exposure demonstrates
that proactive legislative design and political will can operationalize these
safeguards efficiently. Comparative analysis of Brazil and South Africa reveals
both possibilities and constraints within the Global South.
For
TRIPS to align with Sustainable Development Goal 10 as mentioned Global
Inequalities, member states must maintained regulatory autonomy, strengthen
domestic capacity, and resist excessive TRIPS-Plus commitments. A deliberated
and equity-centred interpretation abides critical to ensuring that intellectual
property law serves public welfare rather than undermines it.
[1] WTO, TRIPS Agreement.
[2] Cecilia Oh, “TRIPS and pharmaceuticals: A case of corporate profits
over health”, Third World Network, August-September 2000. Available from https://twn.my/title/twr120a.htm.
[3] Carlos M. Correa, Integrating Public Health Concerns into Patent
Legislation in Developing Countries
(Geneva. South Centre, 2000). Available from https://www.southcentre.int/wp- content /uploads/2017/06/Bk 2000
Integrating-Public-Health-Concerns-into-Patent-Legislation EN.pdf. 4 Carlos M. Correa, "Interpreting the Flexibilities Under the
TRIPS Agreement", in Carlos M. Correa and Reto M. Hilty, eds., Access to
Medicines and Vaccines: Implementing Flexibilities Under Intellectual Property
Law (Springer, 2022). Available from
https://doi.org/10.1007/978-3-030-83114-1 1. 5 WTO, TRIPS Agreement, Art. 27-30.
[4] Ibid, Art. 31.
[5] Ibid., arts. 6, 30, 39.3. Also see Correa, "Interpreting the
Flexibilities Under the TRIPS Agreement."
[6] World Trade Organization, document WT/L/971. Available from
https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/WT/L/971.pdf.
[7] South Centre, “A Public Health Related Approach to Intellectual
Property Rights: Public Health Related Flexibilities in the TRIPS Agreement”.
Available from
https://ipaccessmeds.southcentre.int/wpcontent/uploads/2018/12/Public-Health-Related-Flexibilities-in-the-TRIPS-Agreement.pdf.
[8] World Trade Organization, document WT/MIN(01)/DEC/2, Available from
https://www.wto.org/english/thewto e/minist e/min01 e/
trips e.htm 11 Ibid, Para 4.
[9] UNHLP, "Final Report".
[10] International Covenant on Economic, Social and Cultural Rights
(1966), art. 12.
[11] United Nations Committee on Economic Social and Cultural Rights,
document E/C. 12/2000/4, para,43.
[12] Ibid, paras, 43-44.
[13] UNHRC, A/HRC/RES/12/24
[14] United Nations Human Rights Council, document A/HRC/23/14.
Available from
http://daccessods.un.org/access.nsf/Get?Open&DS=A/HRC/RES/23/14&Lang=E
[15] See, e.g., United Nations General Assembly, document A/HRC/11/12.
Available from https://digitallibrary.un.org/record/652915?v=pdf#files.
[16] The Patents Act, No. 39 of 1970, § 84 (India).
[17] Carlos Correa, Intellectual Property Rights and the Use of
Compulsory Licenses: Options for Developing Countries, 6 S. Ctr. Res. Papers
(2016).
[18] Agreement on Trade-Related Aspects of Intellectual Property Rights
art. 31, Apr. 15, 1994, 1869 U.N.T.S. 299.
[19] The Patents Act, No. 39 of 1970, § 84 (India).
[20] Ibid.
[21] Natco Pharma Ltd. v. Bayer Corp., Compulsory License Application
No. 1 of 2011 (Controller of Patents, India Mar. 9, 2012).
[22] Frederick M. Abbott, The WTO Medicines Decision: World
Pharmaceutical Trade and the Protection of Public Health, 99 Am. J. Int’l L.
317 (2005).
[23] Ellen ’t Hoen, TRIPS, Pharmaceutical Patents and Access to
Essential Medicines, 3 Chi. J. Int’l L. 27 (2002).
[24] World Health Organization, Public Health, Innovation and
Intellectual Property Rights (2006).
How to Cite This Article
DR. SYED MOHSIN RAZA, Evaluating TRIPS Flexibilities and Public Welfare Strategies in India and Developing Jurisdictions., White Black Legal – International Law Journal, ISSN: 2581-8503, Vol. 4, Issue 1, September 2026, pp. 811-824. Available at: https://www.whiteblacklegal.co.in/public/details/evaluating-trips-flexibilities-and-public-welfare-strategies-in-india-and-developing-jurisdictions
Author & Publication Record
Authors: DR. SYED MOHSIN RAZA
Registration ID: 107100 | Published Paper ID: WBL7100
Year: Sep- 2026 | Volume: 4 | Issue: 1
Approved ISSN: 2581-8503 | Country: Delhi, India
Page No.: 811-824
Full Text Preview
Open in New Tab
Copied